LATEST NEWS:  PLUS Provides Shareholder Update

Delivering More For Patients


We are committed to developing breakthrough treatments that provide improved safety, efficacy, and convenience for patients battling cancer and rare diseases.  Our proprietary nanotechnology platform reformulates conventional medicines to help people lead longer and healthier lives.


Development Is In Our DNA

There are many reasons why we believe we possess the capacity and experience to develop and manufacture large-scale, sophisticated nanotechnology-encapsulated cytotoxic drugs that succesfully meet patient needs around the globe:

A fully GMP-compliant, validated, state-of-the-art, U.S. development and manufacturing facility supported by an ICH-compliant Quality Management System.

A 10,000 square foot space with ISO Class 7 and 8 cleanrooms, including a negative pressure room for managing hazardous drugs.

A dedicated analytical chemistry lab with multiple High Performance Liquid Chromatography (HPLC) systems with multiple detector capability, an environmental monitoring lab, and a fully qualified Water For Injection (WFI) system onsite. 

Decades of drug delivery development experience with combination products and liposomal encapsulation, resulting in the completion of multiple successful clinical trials in the U.S. and internationally.

Selective Tumor Targeting

While nanotechnology-based drug delivery systems have been used clinically for some time, not all of them are equally effective.  We are taking a unique design approach with widely-used chemotherapy drugs, using our patented liposomal formulation to elevate drug delivery and performance.

DocePLUS Product Candidate